WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002033072) DEGRADED TPO AGONIST ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/033072    International Application No.:    PCT/JP2001/009259
Publication Date: 25.04.2002 International Filing Date: 22.10.2001
Chapter 2 Demand Filed:    20.12.2001    
IPC:
C07K 16/24 (2006.01), C07K 16/28 (2006.01)
Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome Kita-ku, Tokyo 115-8543 (JP) (For All Designated States Except US).
TSUCHIYA, Masayuki [JP/JP]; (JP) (For US Only).
OHTOMO, Toshihiko [JP/JP]; (JP) (For US Only).
YABUTA, Naohiro [JP/JP]; (JP) (For US Only).
TSUNODA, Hiroyuki [JP/JP]; (JP) (For US Only).
ORITA, Tetsuro [JP/JP]; (JP) (For US Only)
Inventors: TSUCHIYA, Masayuki; (JP).
OHTOMO, Toshihiko; (JP).
YABUTA, Naohiro; (JP).
TSUNODA, Hiroyuki; (JP).
ORITA, Tetsuro; (JP)
Agent: TAKAGI, Chiyoshi; Kojimachi Koyo Bldg. 10, Kojimachi 1-chome Chiyoda-ku, Tokyo 102-0083 (JP)
Priority Data:
2000-321821 20.10.2000 JP
PCT/JP01/03288 17.04.2001 JP
2001-277314 12.09.2001 JP
Title (EN) DEGRADED TPO AGONIST ANTIBODY
(FR) ANTICORPS DEGRADE, AGONISTE DE TPO
Abstract: front page image
(EN)A modified antibody containing at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which transduces a signal into cells by crosslinking a TPO receptor to thereby exert TPO agonism. Because of being usable as a TPO signal transduction agonist, this modified antibody is useful as a preventive and/or a remedy for blood diseases in which platelet reduction participates, thrmobopenia following chemotherapy for cancer or leukemia, etc.
(FR)L'invention concerne un anticorps modifié contenant au moins deux domaines V de chaîne H et au moins deux domaines V de chaîne L d'un anticorps monoclonal, lequel transduit un signal dans des cellules par réticulation d'un récepteur de la thrombopoïétine (TPO), de manière à agoniser TPO. Etant donné que cet anticorps peut être utilisé en tant qu'agoniste de transduction du signal de TPO, il est utile à titre préventif et/ou curatif dans des maladies du sang dans lesquelles il se produit une réduction des plaquettes, dans la thrombopénie consécutive à une chimiothérapie de cancer ou de leucémie, etc..
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)